Table 4.

Incremental Utility of Biomarkers Over Clinical Risk Factors

	Composite	LVH_80	LVSD_MILDGR	LVSD_MODSEV
C‐statistic
Standard risk factors (1)	0.765 (0.742 to 0.788)	0.778 (0.755 to 0.801)	0.763 (0.714 to 0.812)	0.925 (0.892 to 0.958)
Standard risk factors+BNP (2)	0.770 (0.747 to 0.793)	0.783 (0.760 to 0.806)	0.769 (0.722 to 0.817)	0.931 (0.897 to 0.965)
Standard risk factors+biomarkers* (3)	0.774 (0.751 to 0.796)	0.786 (0.763 to 0.808)	0.782 (0.736 to 0.828)	N/A
P Value for difference (1 vs 3)	0.03	0.03	0.14	0.40
P Value for difference (2 vs 3)	0.13	0.20	0.15	N/A
NRI
NRI (1 vs 3)	0.220 (0.127 to 0.313)	0.246 (0.148 to 0.345)	0.395 (0.227 to 0.562)	0.505 (0.237 to 0.773)
NRI (2 vs 3)	0.212 (0.119 to 0.305)	0.243 (0.145 to 0.340)	0.207 (0.037 to 0.376)	N/A
P Value for NRI (1 vs 3)	<0.0001	<0.0001	<0.0001	0.0004
P Value for NRI (2 vs 3)	<0.0001	<0.0001	0.02	N/A

BNP indicates B‐type natriuretic peptide; LVH, left ventricular hypertrophy; LVSD, left ventricular systolic dysfunction; LVSD_MILDGR, mild/greater LVSD; LVSD_MODSEV, moderate/severe LVSD; N/A, non‐applicable, since models (2) and (3) were identical for LVSD_MODSEV; NRI, net reclassification improvement.

^*Model includes risk factors, BNP, and the biomarker that was significantly associated with each outcome.